arrow
R

Răzvan Cristescu

merck & co., inc.
H指数:42
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapy

潜在生物标志物与接受帕博利珠单抗或化疗治疗的转移性三阴性乳腺癌患者临床结局的关联

2025-10-020
OA
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study

高风险、早期、三阴性乳腺癌患者对新辅助培美曲塞联合化疗反应的分子决定因素:开放标签、多队列1b期KEYNOTE-173研究的探索性分析

2025-03-110
OA
Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma

III期随机CLEAR试验的生物标志物分析:lenvatinib联合pembrolizumab与sunitinib治疗晚期肾细胞癌的比较

2024-12-012
OAAI
Association of circulating free DNA (cfDNA) maximum variant allele frequency (mVAF) levels with clinical outcomes in patients (pts) with metastatic nonsquamous non-small cell lung cancer (NSCLC) treated with pembrolizumab (pembro) plus chemotherapy (chemo) in the phase 2 KEYNOTE-782 trial
2024-04-050
PRE
Association of gene expression profiles and clinical outcomes in patients with locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma treated with pembrolizumab in KEYNOTE-629
2024-04-050
PRE
Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146
2024-01-193
OAAI
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results
2023-07-1014
PRE
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC
2023-01-0133
OA